Investment
Features
FeesSafety
Academy
More
Pluang+

Compare W W Grainger Inc (GWW) vs Medpace Holdings Inc (MEDP) Price & Performance

W W Grainger IncTrade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

W W Grainger Inc vs Medpace Holdings Inc — how do they compare? W W Grainger Inc trades at $1,305.49 (market cap $61.32B), while Medpace Holdings Inc trades at $597.39 (market cap $16.90B). The key difference: W W Grainger Inc is far larger — about 3.6× Medpace Holdings Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.

GWWMEDP
Market Cap
$61.32B$16.90B
Sector
TechnologyTechnology
52-Week High
$1.40K$620.59
52-Week Low
$918.18$393.42
Enterprise Value
$63.53B$16.52B
Dividend Yield
0.77%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

W W Grainger Inc

W.W. Grainger (GWW) trades at $1,304.88, up 0.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 results, beating EPS and revenue estimates, and raised its full-year outlook. Revenue grew to $18.8 billion in 2026, with a net income margin of 9.92%. Analyst consensus is a 'Hold' with a $1,320 price target, though institutional sentiment is mixed amid high valuation multiples.

GWW's earnings momentum and market share gains support upside potential, but elevated P/E of 33.19 and bearish technicals pose near-term risks. Investors should weigh robust fundamentals against valuation concerns and macroeconomic pressures affecting industrial demand.

Medpace Holdings Inc

MEDP trades at $596.98, down 0.9% on the day but near its 52-week highs. The stock shows strong technical momentum with bullish moving averages and recent golden cross formation. Fundamentally, the company delivered three consecutive quarterly earnings beats with Q2 2026 EPS of $4.25 beating expectations of $3.98. Revenue growth remains robust at 17.2% year-over-year in Q2 2026, supported by record net bookings and a $3.0 billion backlog.

MEDP presents a growth story with strong fundamentals but trades at premium valuations (P/E 35.58, P/S 6.27). The primary investment opportunity lies in continued execution on record bookings and backlog conversion. Key risks include the ongoing shareholder litigation investigation and potential valuation compression if growth moderates. Analyst consensus targets $599.57 with 21% buy ratings, suggesting limited near-term upside from current levels.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About W W Grainger Inc

Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.

Read more on GWW

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP